Visit website

Senior Scientist - mRNA Sequence Design and Optimization

  • Research & Development (Computational)
  • Full-time
  • Hyderabad, IN
  • Remote friendly

2022-09-22 17:19:41 UTC

PopVax is an Indian biotechnology company based in Hyderabad building a novel thermostable, low-cost, and safe second-generation mRNA platform for rationally-designed broadly-protective multi-epitope vaccines. We’re starting with a 4-8 °C refrigerator-stable booster vaccine candidate that is intended to protect against the entire sarbecovirus sub-family, including current and future strains of SARS-CoV-2 (the virus which causes COVID-19), and some other beta-coronaviruses such as MERS-CoV.

We're looking for an experienced researcher or industry practioner with

  1. deep expertise in mRNA sequence design and optimzation for vaccines or therapeutics, including the design and optimization of UTRs and ORF for use in humans,

  2. human codon optimization,

  3. GC and general nucleotide optimization,

  4. translation optimization,

  5. structural optimization (in particular secondary structures), and

  6. RNA folding.

A familiarity with recent research on 'superfolder' RNA structures or protein-expressing circular RNA is a significant plus. A deep understanding and practical facility with computational methods for RNA design and optimization is a must, including the ability to use and debug state-of-the-art but unpolished research code in this area.

While, all things being equal, we prefer candidates who are willing to work in person at one of our wet labs in Hyderabad, we are willing to consider exceptionally-qualified candidates from anywhere in the world who wish to work remotely.

We offer very competitive compensation, comprehensive health insurance covering immediate family (including pre-existing conditions) [note: for Remote candidates, health insurance may vary based on country of residence], and, most importantly, a collaborative work environment focused on solving the cutting-edge multidisciplinary challenges of our novel mRNA platform.